Cargando…
Recombinant Human ADAMTS13 Treatment Improves Myocardial Remodeling and Functionality After Pressure Overload Injury in Mice
BACKGROUND: A disintegrin‐like metalloproteinase with thrombospondin motif type 1 member 13 (ADAMTS13), the von Willebrand factor–cleaving enzyme, decreases leukocyte and platelet recruitment and, thus, reduces thrombosis and inflammation. Recombinant human ADAMTS13 (rhADAMTS13) is a novel drug cand...
Autores principales: | Witsch, Thilo, Martinod, Kimberly, Sorvillo, Nicoletta, Portier, Irina, De Meyer, Simon F., Wagner, Denisa D. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5850234/ https://www.ncbi.nlm.nih.gov/pubmed/29367415 http://dx.doi.org/10.1161/JAHA.117.007004 |
Ejemplares similares
-
ADAMTS13 Deficiency Worsens Colitis and Exogenous ADAMTS13 Administration Decreases Colitis Severity in Mice
por: Zitomersky, Naamah L., et al.
Publicado: (2017) -
Systemic antithrombotic effects of ADAMTS13
por: Chauhan, Anil K., et al.
Publicado: (2006) -
Recombinant ADAMTS 13 in thrombotic thrombocytopenic purpura
por: Scully, Marie, et al.
Publicado: (2017) -
Peptidylarginine deiminase 4 promotes age-related organ fibrosis
por: Martinod, Kimberly, et al.
Publicado: (2017) -
Sirt3 deficiency does not affect venous thrombosis or NETosis despite mild elevation of intracellular ROS in platelets and neutrophils in mice
por: Hayashi, Hideki, et al.
Publicado: (2017)